AstraZeneca's stock has been on a rollercoaster ride with varying predictions and significant involvement from various investment groups. The pharmaceutical company's stock price crossed above its 200-day moving average prompting some to question if it's
time to sell. On the other hand, it's also been touted as a
top growth and
value stock for the long-term. UBS raised its price target for AstraZeneca to $4,925 citing a strong outlook. There has also been substantial movement of stocks by various asset management corporations and investment groups. Despite some decrease in holdings, new investments and shares acquisition also occurred.
AstraZeneca's progression in
cancer drug development within EU received a boost with EMA Application validation. However, news of a
paused £200m expansion in Cambridge affected the share price. The
Q2 results were positively influenced by growth in US and cancer drugs. There are also reports about AstraZeneca considering relocating its stock listing to the US and its CFO selling company shares.
AstraZeneca's stock faced turbulence amidst these developments while analysts remain optimistic.
AstraZeneca Stocks News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Sat, 13 Sep 2025 19:50:41 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor 2
